S100A9 Monoclonal Antibody

1. Acute exercise in children with juvenile idiopathic arthritis induced slightly musculoskeletal leg pain and transient increased plasma calprotectin levels but not IL-6 levels PMID: 30008613
2. neither the inflammatory biomarker calprotectin, nor the tubular biomarkers NGAL and KIM-1, provide robust prognostic information on the loss of renal function in a heterogeneous CKD population. All of them, however, are candidate prognostic biomarkers in primarily inflammatory renal diseases. PMID: 30078006
3. Serum levels of MRP8/MRP14 and MRP6 were up-regulated in patients with Graves" disease (GD) and Hashimoto"s thyroiditis (HT). In addition, mRNA expression of MRP proteins in PBMCs and the thyroid gland was markedly elevated in these patients. PMID: 29656212
4. High MRP14 expression is associated with Rheumatoid Arthritis PMID: 29530998
5. upper limits for normal calprotectin values for neonatal, 6, 12 and 24 months old children, were determined. PMID: 29283308
6. plasma calprotectin was investigated as a disease marker in patients with chronic RA treated with methotrexate (MTX) monotherapy and compared plasma calprotectin with C-reactive protein. PMID: 29228799
7. Calprotectin measured in plasma showed the strongest associations with assessments of disease activity, and ethylenediaminetetraacetic acid-plasma should preferably be used when evaluating disease activity in rheumatoid arthritis patients. PMID: 29278951
8. RAS is a very common inflammatory ulcerative condition of the oral cavity and its etiology is uncertain. Regarded as an inflammatory mechanism, releasing a high level of calprotectin in saliva has been suggested that it may play a role in pathogenesis of RAS. PMID: 29519972
9. Pro-inflammatory proteins S100A9 and tumor necrosis factor-alpha suppress erythropoietin elaboration in myelodysplastic syndromes PMID: 28983059
10. An immunohistochemical investigation revealed that patients with both UC and CD had higher neutrophil and monocyte/macrophage calprotectin-positive cell expression levels, compared with those in the normal controls. Fecal calprotectin was considered a reliable marker for disease activity, and the assessment of fecal calprotectin via POCT showed potential as a rapid and simple measurement in clinical settings. PMID: 29115397
11. To examine the efficacy of faecal calprotectin (FC) and C-reactive protein (CRP) as predictors of small bowel capsule endoscopy SBCE findings in suspected and known Crohn"s disease. PMID: 29466790
12. S100A9, mainly produced by myeloid cells in the BM, is involved in the pathogenesis of MM. S100A9 attracted MM cells to the BM where it provided a survival niche by inducing the growth factors IL6 and IL10, as well as promoting angiogenesis. PMID: 28903971
13. Study identified S100A9 protein to be up-regulated protein in hepatocellular carcinoma (HCC) and demonstrated its potentiality as a candidate for HCC diagnosis. PMID: 27216119
14. In pediatric inflammatory bowel disease treatment groups, a significant inverse association was found between the quality of life and the levels of fecal calprotectin. PMID: 28169974
15. Fecal calprotectin (FC) was elevated in two-thirds of stool specimens of patients with cystic fibrosis (CF). Increased FC was more common in patients with pancreatic insufficiency. Whether increased FC reflects intestinal inflammation in patients with CF remains to be determined. PMID: 28207476
16. Authors found that downregulation of S100A9 significantly reduced the expression of NF-kappaB, phosphorylation of NF-kappaB and Bcl-2, as well as the expression of MMP7 and MMP2. Restoration of NF-kappaB expression sufficiently reversed the inhibitory effects on cell proliferation and invasion induced by S100A9 downregulation in vitro and in vivo. PMID: 28276321
17. Urinary NGAL is a good predictor of mortality in established pediatric acute kidney injury (AKI) of heterogeneous etiology and outperforms calprotectin and KIM-1. Urinary calprotectin and KIM-1 predict renal replacement therapy requirement in pediatric AKI. PMID: 28409285
18. Identify proteins that interact with calgranulin B to suppress the proliferation of colon cancer cells. PMID: 28036279
19. This study demonstrated that S100A9 was detected in the serums of Alzheimer disease patients PMID: 27911324
20. Expression levels of S100A9 and Tenascin-C were correlated with TNM stages and metastasis in colorectal cancer. PMID: 27191989
21. In Guatemalan preschoolers, the median fecal calprotectin value was 58 mg/kg, with a mean of 98 +/- 136 mg/kg and a range from 10 to 950 mg/kg; 61% of values were above the manufacturer"s cut-off for elevated concentration and 51% exceeded an age-adjusted criterion. The central tendency (mean or median) and distribution were generally shifted to the right in relation to comparable reports from children across the world. PMID: 27101538
22. Low S100A9 expression is associated with head and neck neoplasms. PMID: 26883112
23. Calprotectin had the highest association with ultrasound synovitis and predicted treatment response. It may thus be considered as a marker for evaluating inflammation and responsiveness in patients with rheumatoid arthritis on biologic disease-modifying anti-rheumatic drug treatment. PMID: 28081709
24. Data support a role of S100A9 to initiate and amplify the neutrophilic inflammation in asthma, possibly via inducing IL-1beta, IL-17 and IFN-gamma. PMID: 28847516
25. The median faecal calprotectin level was similar in cases with abdominal pain-related functional gastrointestinal disorders (7.8 mug/g, 95% CI: 7.8-8.4) including those with gastritis, and controls (9.1 mug/g, 95% CI: 7.8-11.3).Faecal calprotectin is not a predictor of gastritis and is similar in children with functional abdominal pain symptoms and in controls. PMID: 26913755
26. S100A9 induces anti-apoptotic effect on normal and allergic neutrophils by increasing cytokine secretion of monocytes PMID: 27459393
27. S100A9, a protein previously described to be involved in modulation of inflammatory response, was found to interact with schistosoma MEG-14. PMID: 27639541
28. High calprotectin activity could be demonstrated within the lumen of vermiform appendix specimens following appendectomy for acute appendicitis. PMID: 27118309
29. observations indicate a novel way in which S100A9 may contribute to the pathogenesis of gout, by priming neutrophils to respond to MSUs. PMID: 28550118
30. S100A9 was an ATRA-responsive gene, and PML/RARalpha was necessary for the ATRA-induced expression of S100A9 in acute promyelocytic leukemia (APL) cells. PML/RARalpha and PU.1 were necessary for the ATRA-induced expression of S100A9 in APL cells. Furthermore, S100A9 promoted apoptosis in APL cells and affected cell growth. PMID: 28063140
31. Salivary S100A9 is a biomarker for oral squamous cell carcinoma in a Hungarian population. PMID: 28545132
32. High S100A9 expression is associated with glioblastoma. PMID: 27006175
33. Faecal calprotectin and CRP are predictive of symptomatic relapse and may be valuable in management of paediatric IBD in clinical remission PMID: 28138990
34. These results suggest a preponderant role for the protein S100-A9 as an activator of the NF-kappa B pathway during Chronic lymphocytic leukemia progression and suggest that the leukemic clone can generate an autoactivation loop through S100-A9 expression, NF-kappa B activation, and exosome secretion. PMID: 28596424
35. Fecal calprotectin levels were increased in pediatric subjects who showed signs of severe Clostridium difficile infection (CDI). Increased serum calprotectin levels were associated with increased disease severity in 48 adults with CDI PMID: 27668938
36. High S100A9 expression is associated with lung metastasis in malignant melanoma. PMID: 27151304
37. A significant positive correlation was found between the serum calprotectin and insulin resistance in polycystic ovary syndrome patients. PMID: 27217417
38. these results indicate that CD14 is a co-receptor of TLR4 in the S100A9-induced cytokine response. PMID: 27228163
39. Our data reveals that there is no significant correlation between serum calprotectin and Faecal calprotectin , nor between serum calprotectin and CRP in a large unselected cohort of GI patients. PMID: 28093196
40. The present study demonstrates the potential of calprotectin to distinguish Rheumatoid Arthritis patients in both clinical and ultrasound-defined remission from patients in clinical remission but with residual subclinical disease activity. PMID: 27832086
41. S100A9 and S100A12 may have a role in the pathogenesis of pneumonia: S100A9 and CXCL1 may contribute solely in mild pneumonia, and CCL5 and CXCL11 may contribute in severe pneumonia. PMID: 28381820
42. patients with primary Sjogren"s syndrome have a higher prevalence of carotid atherosclerosis, which is associated with higher serum calprotectin level independent of traditional cardiovascular risk factors. PMID: 27749218
43. Serum calprotectin was significantly increased in inflammatory bowel disease compared with controls. PMID: 27596694
44. Urinary calprotectin is a promising biomarker for the differentiation of prerenal and intrinsic acute renal allograft failure. PMID: 26901081
45. Faecal biomarkers lactoferrin, calprotectin, and PMN-elastase were able to distinguish between ulcerative colitis patients with mucosal healing from clinical remission and mild disease, showed significant correlations with endoscopy, and were predictive of a flare. PMID: 26874351
46. Blocking the interaction between S100A9 and RAGE V domain is a novel route to drug development against cell proliferation. PMID: 27524699
47. The minor allele (T) of the S100A9 variant rs3014866 is associated with lower type 2 diabetes risk in 3 populations of different ancestries. PMID: 27440084
48. fecal calprotectin can be used in management of patients with inflammatory bowel disease PMID: 27688663
49. this paper shows that human gammadelta T cell-antigen-presenting cells stimulate CD4+ T cell responses distinct from those induced by myeloid antigen-presenting cells to promote local barrier defense via mucosal release of IL-22 and calprotectin PMID: 28330898
50. The calprotectin levels in patients with atrial fibrillation were significantly higher than in healthy blood donors and were further increased after cardioversion. PMID: 28276729
51. Following surgery for pediatric Crohn"s disease, fecal calprotectin (FC) decreased significantly. During follow-up, recurrence occurred in 77% of patients. FC >139mug/g at time of endoscopy or FC increase of 79mug/g compared to first postoperative value was suggestive of endoscopic recurrence (Rutgeerts score i2-i4), while FC >101mug/g or increase of 21mug/g indicated histologic recurrence. PMID: 26891835
52. CHI3L1-mediated cell proliferation/survival involves partial downregulation of the pro-apoptotic S100A9 protein that is highly expressed during the acute phase of colitis, by binding to the S100A9 receptor, RAGE (Receptor for Advanced Glycation End products). PMID: 26431492
53. strong expression of S-100 protein by spindle-shaped tumour cells PMID: 27444171
54. Elevated expression of calprotectin is Associated with Behcet"s Disease. PMID: 27642216
55. a significant relation is found between rheumatoid arthritis disease activity and calprotectin levels and other inflammatory parameters PMID: 27094943
56. Results indicate that advanced extranodal NK/T cell lymphoma (ENKL) patients with unfavourable treatment outcomes displayed higher levels of S100A9 and ORM1. PMID: 27021626
57. High fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis PMID: 26919460
58. High fecal Calprotectin Predicts Inflammation in Crohn"s Disease. PMID: 26818420
59. MRC1 and S100A9 may contribute to the determination of the mechanisms and screening involved in CRC. PMID: 26682511
60. Fecal calprotectin could be used as a predictor of endoscopic remission for Asian inflammatory bowel disease patients. PMID: 26730169
61. S100A9 might be a significant role for predicting osteosarcoma prognosis and down-regulation of S100A9 could be used as a potential target for gene therapy. PMID: 27020242
62. Patients with small intestinal lesions consistent with Crohn"s disease had higher levels of fecal calprotectin than those without lesions. PMID: 25824919
63. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn"s Disease. PMID: 26829408
64. Current evidence suggests that serum calprotectin is significantly raised among women with preeclampsia during the third trimester PMID: 26603731
65. Fecal calprotectin is correlated with the extent of affected mucosa as well as severity in ulcerative colitis patients. PMID: 27071448
66. Elevated fecal calprotectin levels in primary Sjogren"s syndrome was associated with concomitant gastrointestinal disease. PMID: 26759247
67. The TSPAN13-to-S100A9 ratio was selected to determine the diagnostic value of urinary nucleic acids in prostate cancer (PCa) (P = 0.037) and shown to be significantly higher in PCa than in benign prostatic hyperplasia. PMID: 26713053
68. Fecal calprotectin level is influenced by the presence of intestinal lesions in Crohn"s disease, in a depth-related manner and by the affected surface. PMID: 26351383
69. Downregulation of S100A9 was observed in 67% of 288 different esophageal squamous cell carcinoma tumors. PMID: 26788548
70. Data show that S100 calcium binding protein A9 (S100A9) mediated interleukin-6 (IL-6) release via the crosstalk of oral cancer cells with monocytes. PMID: 26315114
71. Urinary calprotectin concentrations start rising within 2 hours after ischaemia/reperfusion-induced kidney injury. PMID: 26745147
72. Data indicate that calprotectin is associated with clinical, laboratory and ultrasound disease activity. PMID: 26373925
73. High expression of S100A9 was associated with cervical squamous cell carcinoma. PMID: 25893434
74. Data indicate that fecal calprotectin (FC) concentration can be a noninvasive marker of disease activity in inflammatory bowel diseases (IBD). PMID: 26768632
75. the findings support the putative diagnostic value of S100A9 measurement in serum as a marker for breast cancer PMID: 26653550
76. suggest that S100A9 may be useful as a biomarker for the hepatic and metabolic progression of NAFLD and the non-invasive diagnosis of NASH PMID: 25993652
77. LL37, HMGB1 and S100A9 are increased in serum during exacerbation in COPD patients PMID: 25931489
78. Low S100A9 mRNA levels were associated with Prostate Cancer. PMID: 25348783
79. In bivariate analysis, only calprotectin but not alpha-1 antitrypsin was independently associated with GI-GVHD. PMID: 25605402
80. S100A9 could be viewed as a novel therapeutic target for patients with ER(-)PgR(-) breast cancers. PMID: 26448179
81. the S100A9-induced release of IL-6 and IL-8 from human periodontal ligament cells is dependent on TLR4, but not RAGE. PMID: 26038301
82. Report of an overexpression of S100A9 protein in both PBMCs and serum of patients with subsequent response to the MTX/ETA combination. This protein thus represents an interesting biomarker candidate of therapeutic response in rheumatoid arthritis. PMID: 25546405
83. High fecal calprotectin expression is associated with poor response to therapy in Crohn"s disease. PMID: 25625487
84. High fecal calprotectin is associated with postoperative recurrence of Crohn"s disease. PMID: 25569739
85. MRP14 is an essential propagator of inflammation and potential therapeutic target in pneumococcal meningitis. PMID: 25605866
86. The combination of serum S100A9, SOD3, and MMP9 levels could achieve 92.5% sensitivity and 95% specificity to discriminate between pulmonary tuberculosis and healthy controls. PMID: 25332062
87. The S100A9 binds to RAGE and stimulates RAGE-dependent MAPK signaling cascades, promoting cell growth and invasion in hepatocellular carcinoma. PMID: 25907296
88. Calprotectin is a good serum biomarker with high sensitivity to change upon effective treatment at the group level in spondyloarthritis PMID: 25135077
89. Higher S100A9 expression in epicardial stromal cells is associated with lower adipocyte size. PMID: 24700313
90. Calprotectin promotes apoptosis and the inflammatory response in human periodontal ligament cells via its subunit, S100A9. PMID: 25338166
91. Our results suggest that Id1 promotes breast cancer metastasis by the suppression of S100A9 expression PMID: 24948111
92. Studied calprotectin"s structural behavior upon Zn(2+) and Mn(2+) chelation solely and along with Ca(2+) using fluorescence spectroscopy and circular dichroism to determine the resulting modifications. PMID: 25213023
93. Data indicate that the fecal calprotectin (fCAL) levels of ankylosing spondylitis (AS) patients are higher than the fCAL levels of controls. PMID: 23194008
94. Mean serum levels of calprotectin were significantly higher in patients with ankylosing spondylitis compared with healthy controls. PMID: 24922195
95. increased fecal calprotectin was found to be predictive of diverticulitis recurrence. PMID: 24798630
96. bedside testing for fecal calprotectin is feasible enough in determining candidates for an endoscopic procedure in order to confirm bowel inflammation and is more tightly associated with histological findings than with endoscopic findings. PMID: 25651733
97. the SSc epidermis provides an important source of pro-fibrotic CCN2 and proinflammatory S100A9 in SSc skin, and therefore contributes to the fibrosis and inflammation seen in the disease PMID: 24933320
98. Data indicate that eighteen hybridoma cell strains secreting S100A9 mAbs were obtained, of which 15 showed strong positive reaction to the recombinant protein in Western blotting. . PMID: 25200158
99. Expression of S100A9 and EGFR closely correlates with cisplatin chemoresistance in bladder cancer. PMID: 24631944
100. FC reflects pediatric IBD severity and activity better than M2-PK. This difference is particularly pronounced when identifying patients with mild UC and UC in remission. PMID: 24649481

Show More

Hide All

HGNC: 10499

OMIM: 123886

KEGG: hsa:6280

STRING: 9606.ENSP00000357727

UniGene: Hs.112405